2007 Key Highlights
- Strong product sales growth
- Positive cash flow
- Solid progress in pipeline
- Key partnerships
- Fast–track status granted by
FDA for rabies monoclonal
antibody cocktail - Record monoclonal antibody production yields of 15 grams
per liter on PER.C6®
Total revenue and other operating income in 2007
An increase to €213.1m in 2007 compared to €140.9m in 2006.
Gross margin in 2007
Significant improvement from 31% in 2006 to 34% in 2007.
Operating net cash flow in 2007
Turnaround from negative €54.0m in 2006 to €22.2m in 2007.